So far, China has made no official public threat about weaponizing its dominant position in this segment of the ...

Hedge funds revealed their top investment ideas, ranging from Chinese self-driving taxis, an Indian drug retailer, to a ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed ...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

As geopolitical tensions prompt global pharmaceutical giants to pivot away from China, India's Contract Development and ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

US President Donald Trump on May 23 threatened to impose a 50 percent tariff on all imports from the European Union.

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...